Epidemiology and survival factors for sarcoma patients in minority populations: a SEER-retrospective study.

Autor:	Dahl V; Department of Education, The University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States., Lee Y; Department of Education, The University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States., Wagner JD; Department of Education, The University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States., Moore M; Department of Education, The University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States., Pretell-Mazzini J; Musculoskeletal Oncology Surgeon, Chief of Musculoskeletal Oncology Division, Miami Cancer Institute, Baptist Health System, Miami, Florida, United States.
Jazyk:	angličtina
Zdroj:	Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology [Rep Pract Oncol Radiother] 2023 Jul 25; Vol. 28 (3), pp. 370-378. Date of Electronic Publication: 2023 Jul 25 (Print Publication: 2023).
DOI:	10.5603/RPOR.a2023.0041
Abstrakt:	Background: Epidemiologic studies have demonstrated race as a predictor of worse oncological outcomes. To better understand the effect of race on oncological outcomes, we utilized the Surveillance, Epidemiology, and End Results (SEER) database to determine what treatment courses are provided to minority patients and how this impacts survival. Materials and Methods: A retrospective review of bone and soft tissue sarcoma cases was performed using the SEER database for a minimum 5-year survival rate (SR) using Kaplan-Meier curves. Categorical variables were compared using Pearson's χ 2 test and Cramer V. Kaplan-Meier curves were used to determine survival rates (SR) and Cox regression analysis was used to determine hazard ratios (HRs). Results: Races that had an increased risk of death included Native American/Alaska Native (NA/AN) [hazard ratio (HR): 1.36, 95% confidence interval (CI): 1.049-1.761, p = 0.020) and Black (HR = 1.17, 95% CI: 1.091-1.256, p < 0.001). NA/AN individuals had the lowest SR (5-year SR = 70.9%, 95% CI: 63.8-78.0%, p < 0.001). The rate of metastasis at diagnosis for each race was 13.07% - Hispanic, 10.62% - NA/AN, 12.77% - Black, 10.61% - Asian/Pacific Islander (A/PI), and 9.02% - White individuals (p < 0.001). There were increases in the rate of metastasis at diagnosis and decreases in rates of surgical excision for Hispanic and Black patients (p < 0.001). Conclusion: Race is determined to be an independent risk factor for death in NA/AN and Black patients with sarcomas of the extremities. Access to healthcare and delay in seeking treatment may contribute to higher rates of metastasis upon diagnosis for minority patients, and decreased rates of surgical excision could be associated with poor follow up and lack of resources. Competing Interests: Conflicts of interest and Funding The authors, their immediate family, and any research foundation with which they are affiliated did not receive any financial payments or other benefits from any commercial entity related to the subject of this article. There are no relevant disclosures. We have no conflicts of interest. The Manuscript submitted does not contain information about medical device(s)/drug(s). All authors significantly contributed to the document and have reviewed the final manuscript. (© 2023 Greater Poland Cancer Centre.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu